ALK and non-small cell lung carcinoma: ICI monotherapy (pembrolizumab, atezolizumab, and cemiplimab) has significantly improved survival outcomes (PFS or OS) compared with chemotherapy in the first-line treatment for advanced NSCLC with PD-L1 expression of at least 50% and without epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS oncogene 1 (ROS1) aberrations [12,21,24].